Biomed. Papers 147(1), 11-17 (2003) | DOI: 10.5507/bp.2003.002

THE SIGNIFICANCE OF KEY REGULATORS OF APOPTOSIS IN THE DEVELOPMENT AND PROGNOSIS OF PROSTATE CARCINOMA. II. PRODUCTS OF SUPPRESSOR GENES RB AND PTEN, CDKI, FAS

Jana Knillová, Zdeněk Kolář, Alice Hlobilková
Laboratory of Molecular Pathology and Institute of Pathology, Faculty of Medicine, Palacký University, 775 15 Olomouc, Czech Republic

The molecular basis for the transition of carcinoma of the prostate from androgen-dependent to androgen-independent growth is largely unknown. Currently for example, it is not clear whether the androgen-independent phenotype is a result of selection of a subgroup of genetically distinct prostate tumour cells which are already hormone-resistant or a genetic adaptation of prostate tumour cells to the hormone therapy itself. It has also been established that prostate tumour transformation is a result of homeostatic control defects, a line of thinking directed toward elucidating the apoptotic profile of prostate tumour cells that may be important in determining prognosis, response to therapy and illness progression. Main consideration in this part of rewiev is given to the role of tumour suppressor genes pRb and PTEN and also the natural inhibitors of cyclin dependent kinases - proteins p21Waf1/Cip1 and p27Kip1. Attention is also given to the role of FAS-mediated pathways in apoptosis induction.

Keywords: Prostate cancer, Apoptosis, Gene expression, Rb, PTEN, CDKI, Fas

Received: April 20, 2003; Published: November 1, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Knillová, J., Kolář, Z., & Hlobilková, A. (2003). THE SIGNIFICANCE OF KEY REGULATORS OF APOPTOSIS IN THE DEVELOPMENT AND PROGNOSIS OF PROSTATE CARCINOMA. II. PRODUCTS OF SUPPRESSOR GENES RB AND PTEN, CDKI, FAS. Biomedical papers, 147(1), 11-17. doi: 10.5507/bp.2003.002
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH. (1991) The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67, 293-302. Go to original source... Go to PubMed...
    2. Rao RN. (1996) Targets for cancer therapy in the cell cycle pathway. Curr Opin Oncol 8, 516-24. Go to original source... Go to PubMed...
    3. Veselý J, Chmela Z, Kryštof V, Hanuš J, Hajdúch M, Strnad M, Havlíček L. (1998) Regulace buněčného cyklu cyklin-dependentními kinázami. Zprav klin farmakol farmac 12, 6-10.
    4. Hofman K, Swinnen JV, Verhoeven G, Heyns W. (2001) E2F activity is biphasically regulated by androgens in LNCaP cells. Biochem Biophys Res Commun 283, 97-101. Go to original source... Go to PubMed...
    5. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995: 147, 545-60.
    6. Bruckheimer EM, Kyprianou N. (2000) Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res 301, 153-62. Go to original source... Go to PubMed...
    7. Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H, Shuin T. (1995) Retinoblastoma gene mutations in primary human prostate cancer. Prostate 27, 314-20. Go to original source... Go to PubMed...
    8. Ruijter E, Montironi R, van de Kaa C, Schalken J. (2001) Molecular changes associated with prostate cancer development. Anal Quant Cytol Histol 23, 67-88.
    9. Phillips SM, Barton CM, Lee SJ, Morton DG, Wallace DM, Lemoine NR, Neoptolemos JP. (1994) Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 70, 1252-7. Go to original source... Go to PubMed...
    10. Brooks JD, Bova GS, Isaacs WB. (1995) Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 26, 35-9. Go to original source... Go to PubMed...
    11. Bruckheimer EM, Gjertsen BT, McDonnell TJ. (1999) Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. Semin Oncol 26, 382-98.
    12. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH. (1990) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247, 712-5. Go to original source... Go to PubMed...
    13. Sarkar FH, Sakr W, Li YW, Macoska J, Ball DE, Crissman JD. (1992) Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas. Prostate 21, 145-52. Go to original source... Go to PubMed...
    14. Tricoli JV, Gumerlock PH, Yao JL, Chi SG, DSouza SA, Nestok BR, deVere White RW. (1996) Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer 15, 108-14. Go to original source... Go to PubMed...
    15. Day ML, Foster RG, Day KC, Zhao X, Humphrey P, Swanson P, Postigo AA, Zhang SH, Dean DC. (1997) Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/ E2F pathway. J Biol Chem 272, 8125-8. Go to original source... Go to PubMed...
    16. Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, Day KC. (1999) E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem 274, 9656-64. Go to original source... Go to PubMed...
    17. Kaltz-Wittmer C, Klenk U, Glaessgen A, Aust DE, Diebold J, Lohrs U, Baretton GB. (2000) FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 80, 1455-64. Go to original source... Go to PubMed...
    18. Dunsmuir WD, Gillett CE, Meyer LC, Young MP, Corbishley C, Eeles RA, Kirby RS. (2000) Molecular markers for predicting prostate cancer stage and survival. BJU Int 86, 869-78. Go to original source... Go to PubMed...
    19. Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, Dahiya R, Cardiff RD, Day ML, Cunha GR. (2000) Sex hormone- induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 60, 6008-17.
    20. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275, 1943-7. Go to original source... Go to PubMed...
    21. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15, 356-62. Go to original source... Go to PubMed...
    22. Ali IU, Schriml LM, Dean M. (1999) Mutational spectra of PTEN/ MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91, 1922-32. Go to original source... Go to PubMed...
    23. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP. (1999) Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99, 323-34. Go to original source... Go to PubMed...
    24. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. (1998) Inhibition of cell migration, spreading, and focal adhesion by tumor suppressor PTEN. Science 280, 1614-7. Go to original source... Go to PubMed...
    25. Ittmann M. (1996) Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res 56, 2143-7.
    26. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. (1998) Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58, 2720-3.
    27. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D. (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57, 4997-5000.
    28. Rubin MA, Gerstein A, Reid K, Bostwick DG, Cheng L, Parsons R, Papadopoulos N. (2000) 10q23. 3 loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph nodenegative (pT2-3, N0) prostate cancer. Hum Pathol 31, 504-8. Go to original source... Go to PubMed...
    29. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS. (1998) Interfocal heterogeneity of PTEN/ MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58, 204-9.
    30. Wang SI, Parsons R, Ittmann M. (1998) Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 4, 811-5.
    31. Forrest MS, Edwards SM, Hamoudi RA, Dearnaley DP, Arden- -Jones A, Dowe A, Murkin A, Kelly J, Teare MD, Easton DF, Knowles MA, Bishop DT, Eeles RA. (2000) No evidence of germline PTEN mutations in familial prostate cancer. J Med Genet 37, 210-2. Go to original source... Go to PubMed...
    32. Cooney KA, Tsou HC, Petty EM, Miesfeldt S, Ping XL, Gruener AC, Peacocke M. (1999) Absence of PTEN germ-line mutations in men with a potential inherited predisposition to prostate cancer. Clin Cancer Res 5, 1387-91.
    33. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Bermon A, Steck PA. (1997) MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57, 5221-5.
    34. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB. (1990) Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87, 8751-5. Go to original source... Go to PubMed...
    35. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59, 4291-6. Go to PubMed...
    36. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA. (1999) Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59, 2551-6.
    37. Sharrard RM, Maitland NJ. (2000) Phenotypic effects of overexpression of the MMAC1 gene in prostate epithelial cells. Br J Cancer 83, 1102-9. Go to original source... Go to PubMed...
    38. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ. (2001) Pten induces chemosensitivity in pten-mutated prostate cancer cells by suppression of bcl-2 expression. J Biol Chem 276, 38830-6. Go to original source... Go to PubMed...
    39. Li P, Nicosia SV, Bai W. (2001) Antagonism between PTEN/ MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem 276, 20444-50. Go to original source... Go to PubMed...
    40. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. (2001) Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27, 222-4. Go to original source... Go to PubMed...
    41. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-4. Go to original source... Go to PubMed...
    42. Waga S, Hannon GJ, Beach D, Stillman B. (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369, 574-8. Go to original source... Go to PubMed...
    43. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-25. Go to original source... Go to PubMed...
    44. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-501. Go to original source... Go to PubMed...
    45. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54, 3391-5.
    46. Bissonnette N, Hunting DJ. (1998) p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 16, 3461-9. Go to original source... Go to PubMed...
    47. Sherr CJ. (1996) Cancer cell cycles. Science 274, 1672-7. Go to original source... Go to PubMed...
    48. Facher EA, Becich MJ, Deka A, Law JC. (1997) Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer 79, 2424-9. Go to original source... Go to PubMed...
    49. Gao X, Chen YQ, Wu N, Grignon DJ, Sakr W, Porter AT, Honn KV. (1995) Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11, 1395-8.
    50. Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW. (1997) Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers. J Urol 158, 636-41. Go to original source... Go to PubMed...
    51. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM. (1999) Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate 39, 8-15. Go to original source... Go to PubMed...
    52. Byrne RL, Horne CH, Robinson MC, Autzen P, Apakama I, Bishop RI, Neal DE, Hamdy FC. (1997) The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 79, 190-5. Go to original source... Go to PubMed...
    53. Sarkar FH, Li Y, Sakr WA, Grignon DJ, Madan SS, Wood DP Jr., Adsay V. (1999) Relationship of p21(WAF1) expression with disease- free survival and biochemical recurrence in prostate adenocarcinomas (PCa). Prostate 40, 256-60. Go to original source... Go to PubMed...
    54. Baretton GB, Klenk U, Diebold J, Schmeller N, Lohrs U. (1999) Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80, 546-55. Go to original source... Go to PubMed...
    55. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon- Cardo C. (1999) Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 5, 2082-8.
    56. Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y. (2001) Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy. Int J Cancer 95, 135-9. Go to original source... Go to PubMed...
    57. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H, Bostwick DG. (2000) The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 6, 1896-9.
    58. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI. (1999) Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91, 1869-76. Go to original source... Go to PubMed...
    59. Wang LG, Ossowski L, Ferrari AC. (2001) Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res 61, 7544-51. Go to PubMed...
    60. Lu S, Tsai SY, Tsai MJ. (1999) Molecular mechanisms of androgen- independent growth of human prostate cancer LNCaP-AI cells. Endocrinology 140, 5054-9. Go to original source... Go to PubMed...
    61. Kolář Z, Murray PG, Scott K, Harrison A, Vojtěšek B, Dušek J. (2000) Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer. Mol Pathol 53, 15-8. Go to original source... Go to PubMed...
    62. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59-66. Go to original source... Go to PubMed...
    63. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. (1999) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154, 313-23. Go to original source... Go to PubMed...
    64. Alessandrini A, Chiaur DS, Pagano M. (1997) Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11, 342-5. Go to original source... Go to PubMed...
    65. Millard SS, Koff A. (1998) Cyclin-dependent kinase inhibitors in restriction point control, genomic stability, and tumorigenesis. J Cell Biochem Suppl 30-31, 37-42. Go to original source... Go to PubMed...
    66. Kibel AS, Christopher M, Faith DA, Bova GS, Goodfellow PJ, Isaacs WB. (2001) Methylation and mutational analysis of p27(kip1) in prostate carcinoma. Prostate 48, 248-53. Go to original source... Go to PubMed...
    67. Kibel AS, Faith DA, Bova GS, Isaacs WB. (2000) Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J Urol 164, 192-6. Go to original source... Go to PubMed...
    68. Guo Y, Sklar GN, Borkowski A, Kyprianou N. (1997) Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 3, 2269-74.
    69. Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, Lohse CM, Wollan P. (1998) Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol 11, 324-8.
    70. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH, van der Kwast TH. (2000) Prognostic value of cell cycle proteins p27 (kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 164, 2156-61. Go to original source... Go to PubMed...
    71. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM. (1998) Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58, 542-8.
    72. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE. (1998) Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159, 941-5. Go to original source... Go to PubMed...
    73. Thomas GV, Schrage MI, Rosenfelt L, Kim JH, Salur G, deKernion JB, Dorey F, Said J, Reiter RE. (2000) Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J Urol 164, 1987-91. Go to original source... Go to PubMed...
    74. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI. (1998) Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90, 1284-91. Go to original source... Go to PubMed...
    75. Fernandez PL, Arce Y, Farre X, Martinez A, Nadal A, Rey MJ, Peiro N, Campo E, Cardesa A. (1999) Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J Pathol 187, 563-6. Go to original source... Go to PubMed...
    76. Agarwal R. (2000) Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60, 1051-9. Go to original source... Go to PubMed...
    77. Ashkenazi A, Dixit VM. (1998) Death receptors: signaling and modulation. Science 281, 1305-8. Go to original source... Go to PubMed...
    78. Pinkoski MJ, Green DR. (1999) Fas ligand, death gene. Cell Death Differ 6, 1174-81. Go to original source... Go to PubMed...
    79. Waring P, Mullbacher A. (1999) Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol 77, 312-7. Go to original source... Go to PubMed...
    80. Schmitz I, Walczak H, Krammer PH, Peter ME. (1999) Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ 6, 821-2. Go to original source... Go to PubMed...
    81. de la Taille A, Chen MW, Shabsigh A, Bagiella E, Kiss A, Buttyan R. (1999) Fas antigen/CD-95 upregulation and activation during castration-induced regression of the rat ventral prostate gland. Prostate 40, 89-96. Go to original source... Go to PubMed...
    82. Diaz JI, Pow-Sang JM, Mora LB, Seigne JD, Cantor AB, Dalton WS. (2000) Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer. Urol Oncol 2000: 5, 149-154. Go to original source... Go to PubMed...
    83. Takayama H, Takakuwa T, Dong Z, Nonomura N, Okuyama A, Nagata S, Aozasa K. (2001) Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens. Lab Invest 81, 283-8. Go to original source... Go to PubMed...
    84. Costa-Pereira AP, Cotter TG. (1999) Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. Br J Cancer 80, 371-8. Go to original source... Go to PubMed...
    85. Ng AY, Bales W, Veltri RW. (2000) Phenylbutyrate-induced apoptosis and differential expression of Bcl-2, Bax, p53 and Fas in human prostate cancer cell lines. Anal Quant Cytol Histol 22, 45-54.
    86. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB. (1997) Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 57, 1758-68.
    87. Gewies A, Rokhlin OW, Cohen MB. (2000) Cytochrome c is involved in Fas-mediated apoptosis of prostatic carcinoma cell lines. Cancer Res 60, 2163-8.
    88. Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaack JB, Duke RC. (1999) Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ 6, 175-82. Go to original source... Go to PubMed...
    89. Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS. (2000) Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2, 348-58. Go to original source... Go to PubMed...

    Return to the content